LSL Pharma Group (TSXV:LSL) Total Operating Expense: C$8.34 Mil (TTM As of Mar. 2026)


TSXV:LSL LSL Pharma Group Inc TSXV:LSL
50 GF Score
Price C$0.32
GF Value C$0.72
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is LSL Pharma Group Total Operating Expense?

LSL Pharma Group TSXV:LSL +3.28% 50 Total Operating Expense is C$8.34 Mil as of Mar. 2026. GuruFocus rates TSXV:LSL with a GF Score™ of 50/100 and a GF Value™ of C$0.72 (Possible Value Trap). The stock has 6 warning signs investors should review.

LSL Pharma Group's Total Operating Expense for the three months ended in Mar. 2026 was C$2.60 Mil. LSL Pharma Group's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was C$8.34 Mil.

LSL Pharma Group Total Operating Expense Related Terms

LSL Pharma Group Total Operating Expense Historical Data

* Premium members only.

The historical data trend for LSL Pharma Group's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LSL Pharma Group Total Operating Expense Chart

LSL Pharma Group Annual Data
Trend Sep20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial 2.59 4.59 5.76 4.94 7.41

LSL Pharma Group Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.67 1.76 1.94 2.05 2.60
TSXV:LSL
50GF Score
LSL Pharma Group Inc TSXV:LSL
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LSL Pharma Group Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$8.34 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of C$8.34 Mil mean?
LSL Pharma Group (TSXV:LSL) has a Total Operating Expense of C$8.34 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on LSL Pharma Group and its competitors.
Is LSL Pharma Group's Total Operating Expense too high?
LSL Pharma Group's current Total Operating Expense is C$8.34 Mil. Overall, LSL Pharma Group has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does LSL Pharma Group's Total Operating Expense compare to ZTS and UTHR?
LSL Pharma Group's Total Operating Expense of C$8.34 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Drug Manufacturers company?
A good Total Operating Expense depends on the Drug Manufacturers industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on LSL Pharma Group and its competitors. LSL Pharma Group's current Total Operating Expense is C$8.34 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LSL Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, LSL Pharma Group (TSXV:LSL) is currently considered Possible Value Trap. The stock's GF Value™ is C$0.72, compared to a current price of C$0.32 — trading 56.3% below its estimated fair value. The current Total Operating Expense is C$8.34 Mil. LSL Pharma Group's overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For LSL Pharma Group (TSXV:LSL), the current Total Operating Expense is C$8.34 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is LSL Pharma Group (TSXV:LSL) Overvalued in 2026?

Based on GuruFocus' analysis, LSL Pharma Group stock appears to be undervalued. The current stock price of C$0.32 is trading 56.3% below its estimated GF Value™ of C$0.72. GuruFocus considers LSL Pharma Group to be Possible Value Trap.

Key valuation signals for TSXV:LSL:

  • Total Operating Expense: C$8.34 Mil
  • GF Value™: C$0.72 vs. price of C$0.32 (56.3% below fair value)
  • GF Score™: 50/100 with 6 warning signs

No single metric tells the full story. See the TSXV:LSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

LSL Pharma Group Business Description

Address 540, rue d\'Avaugour, Bureau 1800, Boucherville, QC, CAN, J4B 0G6
LSL Pharma Group Inc develops, manufactures and commercializes sterile pharmaceutical products, cosmetic products and natural health products. It operates in three segments CMO activities include four operating entities LSL Laboratory, Dermolab, Du-Var, and VSI; Integrated Eye-care pharmaceutical company which includes sterile Eye-care manufacturing operation; and Private Label Business includes Juno OTC which commercializes pharmaceutical products with a focus on private label, over the counter (OTC) products. It derives majority of revenue from CMO activities segment.
50GF Score

Get the complete analysis for TSXV:LSL

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.32
Price
C$0.72
GF Value